GPP
DAWN

Great Point Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Great Point Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-141,526
Closed -$1.89M – 43
2023
Q1 		$1.89M Sell
141,526
-402,925
-74% -$7.87M 0.37% 37
2022
Q4 		$11.7M Buy
544,451
+473,830
+671% +$9.72M 2.3% 18
2022
Q3 		$1.42M Buy
+70,621
New +$1.5M 0.34% 38

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

Great Point Partners's DAWN Position: Q2 2023 in Review

Great Point Partners sold out of Day One Biopharmaceuticals (DAWN) in Q2 2023, closing a stake of 141,526 shares — an estimated $1.89M sold.

Great Point Partners first reported a position in DAWN in Q3 2022 and held it in 3 quarters. The position peaked at $11.7M in Q4 2022. 140 funds tracked by Wall St. Rank hold DAWN as of Q2 2023.

  • Great Point Partners reported no remaining Day One Biopharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Great Point Partners sold 141,526 Day One Biopharmaceuticals shares in Q2 2023, an estimated $1.89M.
  • Great Point Partners first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Great Point Partners's Day One Biopharmaceuticals position peaked at $11.7M in Q4 2022.
  • 140 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2023.

Based on Great Point Partners's 13F filing for Q2 2023, filed 14 Aug 2023.